We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Portable, Battery-Powered Device Combined with Rapid, Highly Sensitive and Accurate Assay Enables COVID-19 Testing Anytime, Anywhere

By LabMedica International staff writers
Posted on 20 May 2021
Print article
Image: Researchers have developed a new approach to coronavirus testing, creating the first hand-held, battery-powered testing device that can yield accurate results in half an hour. The device can simultaneously test for multiple genes, researchers report (Photo courtesy of Photo by L. Brian Stauffer)
Image: Researchers have developed a new approach to coronavirus testing, creating the first hand-held, battery-powered testing device that can yield accurate results in half an hour. The device can simultaneously test for multiple genes, researchers report (Photo courtesy of Photo by L. Brian Stauffer)
A new coronavirus test can get accurate results from a saliva sample in less than 30 minutes and detect as little as one viral particle per 1-microliter drop of fluid.

Many of the components of the hand-held device used in this technology developed by researchers at the University of Illinois at Urbana-Champaign (Champaign, IL, USA) can be 3D-printed. Though it is still in the prototype stage, the device is estimated to cost less than USD 78 and the reagents and other materials needed for testing would amount to USD 6-7 per test, the researchers found.

Current coronavirus testing technologies are complex, expensive, time-consuming and require bulky equipment and expert analysts, whereas the new device can be operated by anyone with minimal training who is careful when loading samples. The innovation was made possible by their recent discovery of a system for making artificial restriction enzymes that can be programmed to recognize and cleave specific genes in an organism’s genome. In the new device, these enzymes carry DNA guides that tag the viral genes of interest. The enzyme cleaves the genes, which have been tagged with a dye that fluoresces only after the genes are cut. The resulting fluorescence signals that those genes are present – a positive test result.

The new technology, called Scalable and Portable Testing, does away with the complicated process of heating and cooling each sample to get results, as many current testing protocols require. SPOT also can detect multiple genes per sample, making it more accurate than single-gene tests, which can yield incorrect or inconclusive results. Another advantage is that it utilizes saliva, which is easier to collect and less invasive than a nasal swab.

The research team tested SPOT using 104 clinical saliva samples. They found that it accurately identified 28 out of 30 SARS-CoV-2-positive samples and 73 of 74 SARS-CoV-2-negative samples. The researchers also tested SPOT with samples containing - or lacking - the influenza virus, the new coronavirus and three other human coronaviruses. It accurately identified samples containing the new coronavirus, whether or not other viruses were present in the sample. The SPOT system also may be useful for detecting genetic markers of certain types of cancer in saliva.

“We developed a rapid, highly sensitive and accurate assay, and a portable, battery-powered device for COVID-19 testing that can be used anywhere at any time,” said University of Illinois Urbana-Champaign chemical and biomolecular engineering professor Huimin Zhao, who led the research. “One key advantage to this technology is its multiplexing capability, so in principle, we can detect many viruses simultaneously using the same device.”

Related Links:
University of Illinois at Urbana-Champaign

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.